Antivirals Market Report 2026

Antivirals Market Overview

• Antivirals market size has reached to $114.4 billion in 2025 • Expected to grow to $163.33 billion in 2030 at a compound annual growth rate (CAGR) of 7.5% • Growth Driver: Increasing Incidence Of Influenza Driving Market Growth Due To Rising Demand For Antiviral Treatments • Market Trend: Innovative Oral Antiviral Treatments Enhancing Patient Compliance And Accessibility In The Fight Against Viral Infections • North America was the largest region in 2025 and Middle East is the fastest growing region.

What Is Covered Under Antivirals Market?

Antivirals are medications designed to treat viral infections by inhibiting the replication of viruses within the host's cells. Unlike antibiotics, which target bacteria, antivirals are specifically used to combat viruses such as the flu, HIV, or hepatitis. They work by interfering with various stages of a virus's lifecycle, helping to reduce the severity and duration of an infection. The main types of anti-viral drug therapy are branded and generic. The various drug classes involved are DNA polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, neuraminidase inhibitors, and others that are used for HIV, hepatitis, herpes, influenza, and others. Reverse-transcriptase inhibitors (RTIs) are a type of antiretroviral medication used to treat HIV infection or AIDS, as well as hepatitis B in some cases.

What Is The Antivirals Market Growth Forecast?

The antivirals market size is expected to see strong growth in the next few years. It will grow to $163.33 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to emerging viral threats, investment in antiviral r&d, increased vaccination and treatment integration, global health initiatives, demand for rapid-response therapeutics. Major trends in the forecast period include rising demand for broad-spectrum antivirals, growing focus on pandemic preparedness, expansion of generic antiviral drugs, increased use in chronic viral infections, development of novel mechanism antivirals.

What Is The Driver Of The Antivirals Market?

The increasing incidence of influenza is anticipated to propel the growth of the antiviral market going forward. Influenza, also called flu, is a highly contagious viral respiratory infection caused by influenza viruses that affect the nose, throat, and lungs. The rising prevalence of influenza is primarily due to colder weather and indoor crowding, which allow the virus to survive longer and facilitate person-to-person transmission in proximity. Antivirals are used for the treatment of influenza and are designed to inhibit the replication and spread of influenza viruses within the body. For instance, in November 2024, according to the Centers for Disease Control and Prevention, a US-based national public health agency, the 2023 to 2024 influenza season was estimated to be associated with 40 million illnesses, 18 million medical visits, 470,000 hospitalizations, and 28,000 deaths. Therefore, the increasing incidence of influenza is driving the growth of the antiviral industry.

Key Players In The Global Antivirals Market

Major companies operating in the antivirals market are AbbVie Inc., Bristol-Myers-Squibb Co., Chemical Industrial & Pharmaceutical Laboratories Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson & Johnson Services Ltd., Merck & Co. Inc., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Abbott Laboratories, Schering-Plough Corporation, Pfizer Inc., Sanofi-Synthélabo Ltd., Inovio Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., AVI Biopharma International Ltd., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Biogen Inc., Genentech USA Inc., Vertex Pharmaceuticals Inc.

Global Antivirals Market Trends and Insights

Major companies operating in the antiviral market are focusing on developing innovative treatments such as oral antiviral treatment to improve patient compliance, enhance accessibility, reduce healthcare costs, and provide more convenient and effective options for managing viral infections. Oral antiviral treatment refers to medications taken by mouth to treat viral infections. These treatments work by inhibiting the ability of viruses to replicate or spread within the body, helping to reduce the severity and duration of the infection. For instance, in May 2023, Pfizer, a US-based company that offers pharmaceuticals announced the approval of Paxlovid, marking it as the first oral antiviral treatment for COVID-19 in adults by the Food and Drug Administration, a US-based government agency. This approval is particularly significant as it provides a new therapeutic option for managing COVID-19, especially in a context where the pandemic is transitioning towards an endemic phase. Paxlovid is specifically indicated for adults with mild-to-moderate COVID-19 who are at high risk for progression to severe disease, including hospitalization or death.

Global Antivirals Market Trends and Insights

Major companies operating in the antiviral market are focused on developing advanced therapeutic solutions, such as antiviral treatments, to enhance patient outcomes and reduce viral transmission. Antiviral treatments are essential for controlling viral infections and preventing complications in affected patients. For instance, in August 2024, Red Queen’s Technology, a US-based pharmaceutical company, launched versatile antivirals. Apple Tree Partners has invested $55 million in Red Queen Therapeutics, a biotech firm developing broad-spectrum antiviral treatments. The company targets infectious pathogens such as COVID-19 and influenza, having already progressed a COVID antiviral through Phase 1 testing and secured U.S. government funding for a pan-influenza drug. Co-founded by Harvard professor Loren Walensky, Red Queen employs stapled lipopeptides to inhibit viral fusion and block viral entry into cells.

What Defines the Antivirals Market?

The anti-viralsmarket consists of sales of amantadine and rimantadine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Antivirals Market Report 2026?

The antivirals market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the antivirals industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.